Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does POMALIDOMIDE Cause Plasma cell myeloma refractory? 280 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 280 reports of Plasma cell myeloma refractory have been filed in association with POMALIDOMIDE (Pomalyst). This represents 0.3% of all adverse event reports for POMALIDOMIDE.

280
Reports of Plasma cell myeloma refractory with POMALIDOMIDE
0.3%
of all POMALIDOMIDE reports
22
Deaths
22
Hospitalizations

How Dangerous Is Plasma cell myeloma refractory From POMALIDOMIDE?

Of the 280 reports, 22 (7.9%) resulted in death, 22 (7.9%) required hospitalization, and 11 (3.9%) were considered life-threatening.

Is Plasma cell myeloma refractory Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for POMALIDOMIDE. However, 280 reports have been filed with the FAERS database.

What Other Side Effects Does POMALIDOMIDE Cause?

Plasma cell myeloma (7,023) Death (6,795) Fatigue (6,530) Pneumonia (5,792) Off label use (3,845) Diarrhoea (3,351) White blood cell count decreased (3,328) Neutropenia (3,029) Rash (2,715) Dyspnoea (2,543)

What Other Drugs Cause Plasma cell myeloma refractory?

BORTEZOMIB (618) DEXAMETHASONE (513) LENALIDOMIDE (489) DARATUMUMAB (404) CARFILZOMIB (386) CYCLOPHOSPHAMIDE (237) IXAZOMIB (132) DOXORUBICIN (115) ETOPOSIDE (90) THALIDOMIDE (89)

Which POMALIDOMIDE Alternatives Have Lower Plasma cell myeloma refractory Risk?

POMALIDOMIDE vs POMALYST POMALIDOMIDE vs PONATINIB POMALIDOMIDE vs PONATINIB\PONATINIB POMALIDOMIDE vs PONESIMOD POMALIDOMIDE vs PORACTANT ALFA

Related Pages

POMALIDOMIDE Full Profile All Plasma cell myeloma refractory Reports All Drugs Causing Plasma cell myeloma refractory POMALIDOMIDE Demographics